• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Dis . Enhanced Severe Acute Respiratory Syndrome Coronavirus 2 Antigen-Specific Systemic Immune Responses in Multisystem Inflammatory Syndr

tetano

Editor, Senior Moderator
J Infect Dis


. 2022 Aug 6;jiac304.
doi: 10.1093/infdis/jiac304. Online ahead of print.
Enhanced Severe Acute Respiratory Syndrome Coronavirus 2 Antigen-Specific Systemic Immune Responses in Multisystem Inflammatory Syndrome in Children and Reversal After Recovery


Nathella Pavan Kumar[SUP] 1 [/SUP], Aishwarya Venkataraman[SUP] 1 [/SUP], Arul Nancy[SUP] 2 [/SUP], Kadar Moideen[SUP] 2 [/SUP], Poovazhagi Varadarjan[SUP] 3 [/SUP], Elilarasi Selladurai[SUP] 3 [/SUP], Thankgavelu Sangaralingam[SUP] 4 [/SUP], Ramya Selvam[SUP] 4 [/SUP], Akshith Thimmaiah[SUP] 4 [/SUP], Suresh Natarajan[SUP] 5 [/SUP], Ganesh Ramasamy[SUP] 5 [/SUP], Syed Hissar[SUP] 1 [/SUP], Umadevi Radayam Ranganathan[SUP] 1 [/SUP], Subash Babu[SUP] 2 [/SUP]



Affiliations

Abstract

Background: Multisystem inflammatory syndrome in children (MIS-C) presents with inflammation and pathology of multiple organs in the pediatric population in the weeks following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Methods: We characterized the SARS-CoV-2 antigen-specific cytokine and chemokine responses in children with MIS-C, coronavirus disease 2019 (COVID-19), and other infectious diseases.
Results: MIS-C is characterized by elevated levels of type 1 (interferon-γ, interleukin [IL] 2), type 2 (IL-4, IL-13), type 17 (IL-17), and other proinflammatory cytokines (IL-1α, IL-6, IL-12p70, IL-18, and granulocyte-macrophage colony-stimulating factor) in comparison to COVID-19 and other infectious diseases following stimulation with SARS-CoV-2-specific antigens. Similarly, upon SARS-CoV-2 antigen stimulation, CCL2, CCL3, and CXCL10 chemokines were significantly elevated in children with MIS-C in comparison to the other 2 groups. Principal component analysis based on these cytokines and chemokines could clearly distinguish MIS-C from both COVID-19 and other infections. In addition, these responses were significantly diminished and normalized 6-9 months after recovery.
Conclusions: Our data suggest that MIS-C is characterized by an enhanced production of cytokines and chemokines that may be associated with disease pathogenesis.

Keywords: COVID-19; MIS-C; SARS-CoV-2; chemokines; cytokines; in vitro cell culture; pediatric population.
 
Back
Top Bottom